{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T22:25:59Z","timestamp":1770503159968,"version":"3.49.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1097\/ftd.0b013e318170a879","type":"journal-article","created":{"date-parts":[[2008,5,21]],"date-time":"2008-05-21T18:45:57Z","timestamp":1211395557000},"page":"394-398","source":"Crossref","is-referenced-by-count":42,"title":["Acute Chlorophenylpiperazine Overdose: A Case Report and Review of the Literature"],"prefix":"10.1097","volume":"30","author":[{"given":"Julia","family":"Kovaleva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elke Devuyst","family":"Ir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter De","family":"Paepe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Verstraete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R5-18-20220123","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/0006-3223(89)90217-5","article-title":"1-(m-Chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain.","volume":"25","author":"Hamik","year":"1989","journal-title":"Biol Psychiatry"},{"key":"R6-18-20220123","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1097\/00001756-199606170-00002","article-title":"m-Chlorophenylpiperazine (mCPP) is an antagonist at the cloned human 5-HT2B receptor.","volume":"7","author":"Thomas","year":"1996","journal-title":"Neuroreport"},{"key":"R7-18-20220123","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s002130051142","article-title":"Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users.","volume":"147","author":"McCann","year":"1999","journal-title":"Psychopharmacology"},{"key":"R8-18-20220123","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/0006-3223(91)90184-N","article-title":"m-Chlorophenylpiperazine as a probe of serotonin function.","volume":"30","author":"Kahn","year":"1991","journal-title":"Biol Psychiatry"},{"key":"R9-18-20220123","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0165-1781(98)00029-8","article-title":"Acute intravenous administration of ondansetron and mCPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results.","volume":"79","author":"Broocks","year":"1998","journal-title":"Psychiatry Res"},{"key":"R10-18-20220123","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1001\/archpsyc.1993.01820200034004","article-title":"m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients.","volume":"50","author":"Krystal","year":"1993","journal-title":"Arch Gen Psychiatry"},{"key":"R11-18-20220123","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0165-1781(94)90001-9","article-title":"Response to meta-chlorophenylpiperazine in panic disorder patients and healthy subjects: influence of reduction in intravenous dosage.","volume":"54","author":"Germine","year":"1994","journal-title":"Psychiatry Res"},{"key":"R12-18-20220123","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/00004714-199710000-00004","article-title":"Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine.","volume":"17","author":"Maes","year":"1997","journal-title":"J Clin Psychopharmacol"},{"key":"R14-18-20220123","first-page":"171","article-title":"Isolation and identification of the major urinary metabolite of m-chlorophenylpiperazine in the rat.","volume":"22","author":"Mayol","year":"1994","journal-title":"Drug Metab Dispos"},{"key":"R15-18-20220123","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.0306-5251.2001.01548.x","article-title":"Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.","volume":"53","author":"Bertilsson","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"R16-18-20220123","first-page":"180","article-title":"Pharmacokinetic meta-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile.","volume":"37","author":"Feuchtl","year":"2004","journal-title":"Psychopharmacology"},{"key":"R17-18-20220123","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00004714-199808000-00007","article-title":"Pharmacokinetic and pharmacodynamic profile of oral and intravenous meta-chlorophenylpiperazine in healthy volunteers.","volume":"18","author":"Gijsman","year":"1998","journal-title":"J Clin Psychopharmacol"},{"key":"R18-18-20220123","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1520\/JFS14783J","article-title":"Postmortem forensic toxicology of trazodone.","volume":"45","author":"Goeringer","year":"2000","journal-title":"J Forensic Sci"},{"key":"R19-18-20220123","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/jat\/29.4.262","article-title":"Investigation of a fatality due to trazodone poisoning: case report and literature review.","volume":"29","author":"Martinez","year":"2005","journal-title":"J Anal Toxicol"},{"key":"R20-18-20220123","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/S0140-6736(07)60674-6","article-title":"Pills, collapse and a negative drug screen.","volume":"369","author":"Wood","year":"2007","journal-title":"Lancet"},{"key":"R21-18-20220123","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00004850-199409000-00005","article-title":"The effects of administration of mCPP on psychological, cognitive, cardiovascular, hormonal and MHPG measurements in human volunteers.","volume":"3","author":"Silverstone","year":"1994","journal-title":"Int Clin Psychopharmacol"},{"key":"R22-18-20220123","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0165-1781(01)00326-2","article-title":"Psychomotor slowing, neuroendocrine responses, and behavioral changes after oral administration of meta-chlorophenylpiperazine in normal volunteers.","volume":"105","author":"Sabbe","year":"2001","journal-title":"Psychiatry Res"},{"key":"R23-18-20220123","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/sj.npp.1300006","article-title":"Central serotonergic effects of m-chlorophenylpiperazine (mCPP) among normal control adolescents.","volume":"28","author":"Ghaziuddin","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"R24-18-20220123","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/0006-3223(94)00235-U","article-title":"m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation.","volume":"38","author":"Goodman","year":"1995","journal-title":"Biol psychiatry"},{"key":"R25-18-20220123","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0306-4530(00)00048-2","article-title":"Neuroendocrine and behavioral responses to mCPP in obsessive-compulsive disorder.","volume":"26","author":"Khanna","year":"2001","journal-title":"Psychoneuroendocrinology"},{"key":"R26-18-20220123","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0893-133X(00)00178-0","article-title":"Low versus standard dose mCPP challenge in obsessive-compulsive patients.","volume":"24","author":"Erzegovesi","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"R27-18-20220123","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/0006-3223(90)90534-9","article-title":"The drug-free period: a methodological issue comment.","volume":"27","author":"Asnis","year":"1990","journal-title":"Biol Psychiatry"},{"key":"R28-18-20220123","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0165-1781(98)00044-4","article-title":"Serotonin syndrome after challenge with the 5-HT agonist meta-chlorophenylpiperazine.","volume":"79","author":"Klaassen","year":"1998","journal-title":"Psychiatry Res"},{"key":"R29-18-20220123","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/01.ftd.0000211812.27558.6e","article-title":"Toxicokinetics of drugs of abuse: current knowledge of the isoenzymes involved in the human metabolism of tetrahydrocannabinol, cocaine, heroin, morphine, and codeine.","volume":"3","author":"Maurer","year":"2006","journal-title":"Ther Drug Monit"},{"key":"R30-18-20220123","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0376-8716(01)00146-6","article-title":"The subjective effects of MDMA and mCPP in moderate MDMA users.","volume":"65","author":"Tancer","year":"2001","journal-title":"Drug Alcohol Depend"},{"key":"R31-18-20220123","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0376-8716(03)00172-8","article-title":"Reinforcing, subjective and physiological effects of MDMA in humans: an comparison with d-amphetamine and mCPP.","volume":"72","author":"Tancer","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"R32-18-20220123","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0006-3223(96)00182-5","article-title":"The meta-chlorophenylpiperazine challenge test in cocaine addicts: hormonal and physiological responses.","volume":"41","author":"Buydens-Branchey","year":"1997","journal-title":"Biol Psychiatry"},{"key":"R33-18-20220123","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1001\/archpsyc.1991.01810280099018","article-title":"Ethanol-like properties of the serotoninergic partial agonist m-chlorophenylpiperazine in chronic alcohol patients.","volume":"48","author":"Benkelfat","year":"1991","journal-title":"Arch Gen Psychiatry"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-200806000-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T20:00:55Z","timestamp":1642968055000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-200806000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e318170a879","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}